References
- 1Hamonet C. Dystonia in the joint hypermobility syndrome (a.k.a. Ehlers- Danlos syndrome, hypermobility type). SOJ Neurol. 2016 Feb 29; 3(1): 1–3. DOI: 10.15226/2374-6858/3/1/00123
- 2Occupational Therapy Institute, University Paris-Est-Creteil, 61 Avenue Du Général De Gaulle, 94010 Créteil, France, Hamonet C. Ehlers-Danlos, Proprioception, Dystonia, Dysautonomy, L-Dopa and Oxgenotherapy’s Efficacy. J Alzheimer’s Neurodegener Dis. 2019 Nov 30; 5(2): 1–4. DOI: 10.24966/AND-9608/100031
- 3Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007 Oct; 13(7): 411–6. DOI: 10.1016/j.parkreldis.2007.02.005
- 4Dashtipour K, Lew M.
Cervical Dystonia . In: Stacy M (ed.). Handbook of dystonia. 2. ed. London: Informa Healthcare; 2012. DOI: 10.3109/9781841848525.010 - 5Camfield L, Ben-Shlomo Y, Warner TT. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. Impact of cervical dystonia on quality of life. Mov Disord. 2002 Jul; 17(4): 838–41. DOI: 10.1002/mds.10127
- 6Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10; 86(19): 1818–26. DOI: 10.1212/WNL.0000000000002560
- 7Dashtipour K, Pedouim F. Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile. Semin Neurol. 2016 Feb 11; 36(1): 29–33. DOI: 10.1055/s-0035-1571213
- 8Mohan A, Chang E. Decompression for botulinum toxin-exacerbated cervical myeloradiculopathy in the setting of congenital stenosis and Arnold–Chiari I malformation. Spinal Cord Ser Cases. 2018 Dec; 4(1): 42. DOI: 10.1038/s41394-018-0077-4
- 9Rubio-Agusti I, Kojovic M, Chandrashekar HS, Edwards MJ, Bhatia KP. Cervical dystonia and joint hypermobility syndrome: A dangerous combination. Mov Disord. 2012 Feb; 27(2): 203–4. DOI: 10.1002/mds.24013
- 10Wang C, Wang E, Lei H. Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series [abstract]. Mov Disord. 2018; 33(suppl 2).
https://www.mdsabstracts.org/abstract/increased-risks-of-botulinum-toxin-injection-in-patients-with-hypermobility-ehlers-danlos-syndrome-a-case-series/ . Accessed April 1, 2021. - 11Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017 Mar; 175(1): 8–26. DOI: 10.1002/ajmg.c.31547
- 12Burling F. Comparison of tetradecyl sulfate versus polidocanol injections for stabilisation of joints that regularly dislocate in an Ehlers-Danlos population. BMJ Open Sport Exerc Med. 2019 Jan; 5(1):
e000481 . DOI: 10.1136/bmjsem-2018-000481 - 13Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clin Med Insights Arthritis Musculoskelet Disord. 2016 Jan; 9: CMAMD.S39160. DOI: 10.4137/CMAMD.S39160
- 14Appendix C: AAN Classification of Evidence for the Rating of a Therapeutic Study. Contin Lifelong Learn Neurol. 2015 Aug; 21: 1169. DOI: 10.1212/01.CON.0000470920.20859.fe
- 15Dashtipour K, Mari Z, Jankovic J, Adler CH, Schwartz M, Brin MF. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019 Oct; 405: 116413. DOI: 10.1016/j.jns.2019.07.031
- 16Stecco C, Day JA. The fascial manipulation technique and its biomechanical model: a guide to the human fascial system. Int J Ther Massage Bodyw. 2010 Mar 17; 3(1): 38–40. DOI: 10.3822/ijtmb.v3i1.78
- 17Delnooz CCS, Veugen LC, Pasman JW, Lapatki BG, van Dijk JP, van de Warrenburg BPC. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia. Eur J Neurol. 2014 Dec; 21(12): 1486–e98. DOI: 10.1111/ene.12517